Susceptible infections
Adult: Initially, 400 mg on the 1st day, followed by 200 mg daily.
Indications and Dosage
Oral
Susceptible infections Adult: Initially, 400 mg on the 1st day, followed by 200 mg daily.
|
||||
Renal Impairment
|
||||
Contraindications
Hypersensitivity; lactation; pregnancy. Patients <18 yr.
|
||||
Special Precautions
Impaired hepatic or renal function; G6PD deficiency; myasthenia gravis; maintain adequate fluid intake; avoid excessive alkalinity of the urine. Avoid exposure to strong sunlight/sunlamp; epilepsy; history of CNS disorders. Discontinue in case of tendon pain, inflammation or rupture. May impair ability to drive and operate machinery. High level of resistance with S. aureus infections. May prolong QT interval. Avoid usage in Methicillin-Resistant S. aureus (MRSA) infections.
|
||||
Adverse Reactions
GI disturbances; CNS effects; hypersensitivity-type reactions; reversible arthralgia; hepatic effects; haematological disturbances; tachycardia; superinfection; pain and irritation at inj site; tendon damage; phloebitis and thrombophloebitis.
|
||||
Drug Interactions
May inhibit hepatic metabolism and clearance of drugs metabolised in the liver e.g. theophylline and caffeine; antacids and metal cations; antineoplastics. Efficacy may be affected when used with histamine H2 antagonists.
|
||||
Lab Interference
Elevated liver enzyme values.
|
||||
Action
Description:
Mechanism of Action: Rufloxacin inhibits DNA gyrase which is essential in bacterial DNA reproduction. It is active against gram-positive, but particularly active against gram-negative bacteria, including salmonella, shigella, campylobacter, neisseria and pseudomonas. Pharmacokinetics: Absorption: Approximately 60% of an oral dose is absorbed. Distribution: About 60-80% bound to plasma proteins. Excretion: Plasma half-life: about 30 hr. Occurs through renal and nonrenal mechanisms. About 21-53% excreted unchanged in urine. |
||||
MIMS Class
|